lenvima tablet
Overview
Lenvima is an approved medicine that contains lenvatinib. It is used to
treat different kinds of cancers. This medication is mainly prescribed to
patients diagnosed with Hepatocellular Carcinoma (liver cancer), Renal
Cell Carcinoma (kidney cancer), and Differentiated Thyroid Cancer.
Purchase the lenvima tablet at a 30% discount on Magicine Pharma.
Generic Name:- Lenvatinib
Manufacturer:- Eisai
Dosage Form:- Capsule
Strength:- 10mg
Composition:- Lenvatinib
Packaging:- 10 capsule (10/strip)
Indication:- Kidney, Thyroid, and Liver cancer
Storage:- Store at room temperature.
Pharmacodynamics Of Lenvima (Lenvatinib)
Lenvatinib is a receptor tyrosine kinase receptor that inhibits the
kinase activities of vascular endothelial growth factor (VEGF)
receptors VEGFR1, VEGFR2, VEGFR3. Lenvatinib also inhibits other
RTKs that have been implicated in pathogenic angiogenesis, tumor
growth, and cancer progression in addition to their normal cellular
functions, including fibroblast growth factor (FGF) receptors FGFR1,
2, 3, and 4; the platelet-derived growth factor receptor alpha
(PDGFRα), KIT, and RET. After the oral administration, the effect of
this medicine can be observed in 1 to 4 hours.

Buy Lenvima tablet

  • 1.
    lenvima tablet Overview Lenvima isan approved medicine that contains lenvatinib. It is used to treat different kinds of cancers. This medication is mainly prescribed to patients diagnosed with Hepatocellular Carcinoma (liver cancer), Renal Cell Carcinoma (kidney cancer), and Differentiated Thyroid Cancer. Purchase the lenvima tablet at a 30% discount on Magicine Pharma.
  • 2.
    Generic Name:- Lenvatinib Manufacturer:-Eisai Dosage Form:- Capsule Strength:- 10mg Composition:- Lenvatinib Packaging:- 10 capsule (10/strip) Indication:- Kidney, Thyroid, and Liver cancer Storage:- Store at room temperature. Pharmacodynamics Of Lenvima (Lenvatinib) Lenvatinib is a receptor tyrosine kinase receptor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1, VEGFR2, VEGFR3. Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET. After the oral administration, the effect of this medicine can be observed in 1 to 4 hours.